SecBot SecBot
PRESS-RELEASE ·Filed Mar 26, 2026

SPRO

Spero Therapeutics, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

Traders should monitor the June 18, 2026 FDA decision as a key catalyst; the strong cash position and reduced burn rate improve the company's runway and reduce near-term dilution risk, while the GSK partnership de-risks commercialization. The sharp improvement in profitability and revenue, driven by collaboration inflows, suggests improved financial sustainability pending regulatory outcome.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$2.33
T+0 close · Mar 26, 2026 · via day close
Latest settled
−7.51%
T+60 · $2.16
Vs SPY
−23.58%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 27 $2.33entry
  2. T+1 · 8mo ago −3.86%α −3.50% · $2.24
  3. T+5 · 8mo ago +12.02%α +8.15% · $2.61
  4. T+20 · 7mo ago +14.59%α +1.85% · $2.67
  5. T+60 · 5mo ago −7.51%α −23.58% · $2.16
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Spero Therapeutics reported a significant turnaround in financial performance for Q4 and full-year 2025, driven by a 177% YoY revenue increase to $41.3M in the quarter, primarily from collaboration payments with GSK and Pfizer, while R&D expenses dropped 80% due to reduced trial activity. The company also announced that the FDA set a PDUFA date of June 18, 2026, for tebipenem HBr, an investigational oral antibiotic for cUTI, with cash reserves of $40.3M expected to fund operations into 2028.

Key Financial Metrics

Revenue
$41.3M
+175.3% YoY
EPS
$0.53

Key Facts

  • Net income of $31.5M in Q4 2025 vs. net loss of $(20.9)M in Q4 2024
  • Total revenue of $41.3M in Q4 2025, up from $15.0M in Q4 2024 (175% YoY growth)
  • Full-year 2025 revenue of $66.8M vs. $48.0M in 2024
  • R&D expenses fell to $5.6M in Q4 2025 from $28.8M in Q4 2024 due to completion of the PIVOT-PO trial
  • FDA set PDUFA date of June 18, 2026, for tebipenem HBr NDA resubmission for cUTI
  • Cash and equivalents: $40.3M as of Dec 31, 2025, expected to fund operations into 2028
  • Received $25M milestone payment from GSK in Q1 2026 for NDA resubmission

Financial Impact

Revenue increased by $18.8M annually and $26.3M quarterly, while R&D costs decreased by $58.3M annually, leading to a $77.1M improvement in net income year-over-year

revenuenet_incomeepsr_and_d_expensecash_flow

Risk Factors

  • FDA approval of tebipenem HBr is not guaranteed and could be delayed or denied
  • Future revenue depends heavily on milestone and collaboration payments, which are non-recurring
  • Commercial success depends on GSK's execution, over which Spero has limited control

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3263404

Track record

17 reports on SPRO

Performance horizon

3 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +8.06% at T+1 after the Jun 17, 2026 report. 4 of 7 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $0.9999 Now $0.9460 −5.39% settles Nov 20
  2. Nov 10, 20266d ago 3 Neutral 2/10 Entry $1.02 Now $0.9460 −7.25% settles Nov 18
  3. Nov 10, 20266d ago 8-K Neutral 2/10 Entry $1.02 Now $0.9460 −7.25% settles Nov 18
  4. Oct 27, 202620d ago 8-K Neutral 2/10 Entry $1.17 to $1.07 Now $0.9460 −19.15% ▼ −8.55% −7.83% vs SPY
  5. Sep 11, 20269w ago EFFECT Bearish 7/10 Entry $1.13 to $1.13 Now $0.9460 +16.28% · 0.00% −0.34% vs SPY
  6. Aug 28, 202611w ago 8-K Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
  7. Aug 28, 202611w ago S-3 Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
  8. Aug 12, 202613w ago Press Release Neutral 4/10 Entry $1.24 to $1.22 Now $0.9460 −23.71% ▼ −1.61% +0.35% vs SPY
  9. Jul 14, 202617w ago 8-K Bullish 8/10 Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
  10. Jul 14, 202617w ago Press Release Bullish 7/10 Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens Wed (10h 26m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 26, 2026